nVerses Capital’s BridgeBio Pharma BBIO Stock Holding History

nVerses Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Buy	+2,753	New	+$193K	0.32%	186

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

nVerses Capital's BBIO Position: Q2 2026 in Review

nVerses Capital opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 2,753 shares worth $205K. The stake represents 0.32% of the portfolio and ranks #186 among its holdings.

339 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

nVerses Capital held 2,753 shares of BridgeBio Pharma worth $205K as of Q2 2026.
BridgeBio Pharma was a new nVerses Capital position in Q2 2026.
BridgeBio Pharma made up 0.32% of nVerses Capital's portfolio in Q2 2026, its #186 holding.
339 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.